Clinical Updatesaxicabtagene ciloleucelB-cell lymphoma
Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care
By MedXY|Jan 13, 2026
This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.
